Real-time enrollment status for this metastatic castration-resistant prostate cancer (mcrpc) clinical trial
Current Status
Recruiting
Checked: October 12, 2026 at 1:45 PM UTC
| NCT Number | NCT06136650 |
| Recruiting Status | Recruiting |
| Condition | Metastatic Castration-resistant Prostate Cancer (mCRPC) |
| Phase | PHASE3 |
| Target Enrollment | 1,314 participants |
| Active Locations | 63 sites in the US |
| Sponsor | Merck Sharp & Dohme LLC |
| Last Updated on CT.gov | October 6, 2026 (6 days ago) |
As of October 12, 2026: Clinical trial NCT06136650 is currently recruiting participants. This phase3 study for metastatic castration-resistant prostate cancer (mcrpc) is actively seeking new participants at 63 locations across the United States. The study is sponsored by Merck Sharp & Dohme LLC. This status information is automatically verified from the official ClinicalTrials.gov registry.
Yes, NCT06136650 is actively recruiting participants as of October 12, 2026. You can check eligibility and apply through HelloStudys.
This trial is recruiting at 63 locations in the United States. View all available locations on the full study page.
Check your eligibility and express interest by completing the application form on the study page. A research coordinator will follow up to discuss next steps.
The official ClinicalTrials.gov record for NCT06136650 was last updated 6 days ago (October 6, 2026). HelloStudys verifies this status automatically.